Literature DB >> 12695746

Thrombotic and fibrinolytic alterations in the aseptic necrosis of femoral head.

Emoke Pósán1, Kálmán Szepesi, Levente Gáspár, Zoltán Csernátony, Jolán Hársfalvi, Eva Ajzner, Anikó Tóth, Miklós Udvardy.   

Abstract

Recent reports seem to support the role of the thrombophilia and decreased fibrinolysis in the aetiopathogenesis of aseptic necrosis of bone. In the present study, haemostatic disturbances were analysed in adults (n = 49) and patients in childhood (Perthes disease) (n = 47) with aseptic necrosis of the femoral head. Fibrinolytic parameters (in vitro clot lysis, plasminogen, plasmatic plasminogen activator inhibitor-1 activity, D-dimer) along with lipoprotein (a) [Lp(a)] and fibrinogen were measured. von Willebrand factor, platelet activation and some thrombophilic factors (activated protein C resistance and factor V Leiden mutation, protein C, protein S activity) were also determined. Impaired fibrinolysis, an increased Lp(a) level along with slow clot lysis and increased platelet activation were found in adult cases. We detected five cases of factor V Leiden mutations (one heterozygotic and four homozygotic) among patients with Perthes disease. The clinical course of the heterozygous case was similar to the usual form of Perthes disease. The most severe form of Perthes disease has been observed in homozygous factor V Leiden mutation cases. The mutation of factor V Leiden per se probably does not induce the development of aseptic necrosis of bone tissue in childhood, but it does play a role in its acceleration. Homozygous factor V Leiden mutation definitely runs a more severe course. On the other hand, in adult cases, the disturbances of haemostasis, impaired fibrinolysis, elevated Lp(a) level, increased platelet activation and slight elevation of fibrinogen might have clinical relevance. Further studies should focus on proving the role of the haemostatic alterations in the pathogenesis of severe forms of aseptic bone necrosis. The use of antithrombotic drugs in order to slow the process of aseptic necrosis also has to be addressed in future surveys.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695746     DOI: 10.1097/01.mbc.0000061299.28953.34

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

1.  Accumulation of LDL/ox-LDL in the necrotic region participates in osteonecrosis of the femoral head: a pathological and in vitro study.

Authors:  Xin-Yuan Wang; Tian-Le Ma; Kang-Ning Chen; Zhi-Ying Pang; Hao Wang; Jun-Ming Huang; Guo-Bin Qi; Chen-Zhong Wang; Zeng-Xin Jiang; Lin-Jing Gong; Zhe Wang; Chang Jiang; Zuo-Qin Yan
Journal:  Lipids Health Dis       Date:  2021-11-25       Impact factor: 3.876

2.  Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head.

Authors:  Charles J Glueck; Richard A Freiberg; Ping Wang
Journal:  Clin Orthop Relat Res       Date:  2008-03-19       Impact factor: 4.176

3.  Risk factors for osteonecrosis of the femoral head in patients with sickle cell disease.

Authors:  A L Akinyoola; I A Adediran; C M Asaleye; A R Bolarinwa
Journal:  Int Orthop       Date:  2008-07-17       Impact factor: 3.075

4.  Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes.

Authors:  Kazutaka Sakamoto; Makoto Osaki; Akira Hozumi; Hisataka Goto; Tatsuya Fukushima; Hideo Baba; Hiroyuki Shindo
Journal:  BMC Musculoskelet Disord       Date:  2011-04-27       Impact factor: 2.362

5.  Idiopathic and secondary osteonecrosis of the femoral head show different thrombophilic changes and normal or higher levels of platelet growth factors.

Authors:  Elisabetta Cenni; Caterina Fotia; Enis Rustemi; Kimitachi Yuasa; Giuseppe Caltavuturo; Armando Giunti; Nicola Baldini
Journal:  Acta Orthop       Date:  2011-02-01       Impact factor: 3.717

6.  The role of hypercoagulability in the development of osteonecrosis of the femoral head.

Authors:  Marios G Lykissas; Ioannis D Gelalis; Ioannis P Kostas-Agnantis; Georgios Vozonelos; Anastasios V Korompilias
Journal:  Orthop Rev (Pavia)       Date:  2012-05-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.